REFERENCES
- Silverberg E, Boring C, Squires TS. Cancer statistics, 1990. CA Cancer J Clin 1990; 40: 9–26.
- Williamson RCN. Pancreatic cancer: The greatest onco-logical challenge. Br Med J 1988; 296: 445–6.
- Glimelius B, Hoffman K, Sjoden P-O, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593–600.
- Carter SK. The integration of chemotherapy into a com-bined modality approach for cancer treatment. IV. Pancreatic adenocarcinoma. Cancer Treat Rev 1975; 2: 192–214.
- Moertel CG. Chemotherapy of gastrointestinal cancer. Clin Gastroenterol 1976; 5: 777–93.
- Smith FP, Hoth DF, Levin B, et al. 5-fluorouracil, adri-amycin and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 1980; 46: 2014–8.
- Wiggins RG, Wooley PV, MacDonald JS, et al. Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer. Cancer 1978; 41: 387–91.
- Bruckner W, Crown J, McKenna A, et al. Leucovorin and 5-fluorouracil as a treatment for disseminated cancer of the pancreas and unknown primary tumors. Cancer Res 1988; 48: 5570–2.
- DeCaprio JA, Mayer RJ, Gonin R, Arbuck SG. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol, 1991; 9: 2128–33.
- Crown J, Casper ES, Botet J, Murray P, Kelsen DP. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991; 9: 1682–6.
- Rubin J, Gallagher JG, Schroeder G, et al. Phase II tri-als of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma. Cancer 1996; 78: 1888-91.
- Weinerman BH, MacCormick RE. A phase II survival comparison of patients with adenocarcinoma of the pancreas treated with 5-fluorouracil and calcium leucovorin versus a matched tumor registry control population. Am J Clin Oncol 1994; 17: 467–9.
- Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2',2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12: 29–34.